Challenges and progress in the development of a serogroup B meningococcal vaccine

被引：2

作者：

Lewis, Susan ^{[1
]}

Sadarangani, Manish ^{[1
]}

Hoe, J. Claire ^{[1
]}

Pollard, Andrew J. ^{[1
]}

机构：

[1] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Dept Paediat,Oxford Vaccine Grp, Oxford OX3 7LJ, England

来源：

EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 06期

关键词：

5CVMB; meningococcal disease; outer membrane protein; outer membrane vesicle vaccine; serogroup B; MEMBRANE-VESICLE VACCINE; INNER-CORE LIPOPOLYSACCHARIDE; MENINGITIDIS GROUP-B; H-BINDING PROTEIN; SYNERGISTIC BACTERICIDAL ACTIVITY; NEISSERIA-LACTAMICA PROTECTS; HUMAN-ANTIBODY RESPONSES; HUMAN SERUM ANTIBODIES; NEW-ZEALAND; ESCHERICHIA-COLI;

D O I：

10.1586/ERV.09.30

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines.

引用

页码：729 / 745

页数：17

共 50 条

[31] Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease
Fischer, M
Carlone, GM
Holst, J
Williams, D
Stephens, DS
Perkins, BA
VACCINE, 1999, 17 (19) : 2377 - 2383
[32] Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation
Chen, Mingliang
Rodrigues, Charlene M. C.
Harrison, Odile B.
Zhang, Chi
Tan, Tian
Chen, Jian
Zhang, Xi
Chen, Min
Maiden, Martin C. J.
SCIENTIFIC REPORTS, 2018, 8
[33] High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland
Wasko, Izabela
Hong, Eva
De Paola, Rosita
Stella, Maria
Moschioni, Monica
Taha, Muhamed-Kheir
Skoczynska, Anna
VACCINE, 2016, 34 (04) : 510 - 515
[34] The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease
Zlotnick, Gary W.
Jones, Thomas R.
Liberator, Paul
Hao, Li
Harris, Shannon
McNeil, Lisa K.
Zhu, Duzhang
Perez, John
Eiden, Joseph
Jansen, Kathrin U.
Anderson, Annaliesa S.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (01) : 5 - 13
[35] Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea-A randomised trial
Lee, Hoan Jong
Choe, Young June
Hong, Young-Jin
Kim, Kyung-Hyo
Park, Su Eun
Kim, Yun-Kyung
Oh, Chi-Eun
Lee, Hyunju
Song, Hyoyoung
Bock, Hans
Casula, Daniela
Bhusal, Chiranjiwi
Arora, Ashwani Kumar
VACCINE, 2016, 34 (09) : 1180 - 1186
[36] Fast Tracking the Vaccine Licensure Process to Control an Epidemic of Serogroup B Meningococcal Disease in New Zealand
Lennon, Diana
Jackson, Catherine
Wong, Sharon
Horsfall, Maraekura
Stewart, Joanna
Reid, Stewart
CLINICAL INFECTIOUS DISEASES, 2009, 49 (04) : 597 - 605
[37] Meningococcal serogroup B disease in Turkey A guess or reality?
Bakir, Mustafa
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (06) : 1721 - 1724
[38] Emerging experience with meningococcal serogroup B protein vaccines
Toneatto, Daniela
Pizza, Mariagrazia
Masignani, Vega
Rappuoli, Rino
EXPERT REVIEW OF VACCINES, 2017, 16 (05) : 433 - 451
[39] Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
Allan R. Tunkel
Current Infectious Disease Reports, 2001, 3 (4) : 350 - 351
[40] Meningococcal serogroup B vaccines: will they live up to expectations?
Zollinger, Wendell D.
Poolman, Jan T.
Maiden, Martin C. J.
EXPERT REVIEW OF VACCINES, 2011, 10 (05) : 559 - 561

← 1 2 3 4 5 →